Liu M, Zhang H X, Zhang L, Zhao J W, Zhou L, Wang B M
Department of Gastroenterology and Hepatology, General Hospital of Tianjin Medical University, Tianjin 300052, China.
Zhonghua Gan Zang Bing Za Zhi. 2022 Nov 20;30(11):1231-1236. doi: 10.3760/cma.j.cn501113-20200819-00466.
To evaluate the potential of receptor-interacting protein 3 (RIP3) as a therapeutic target for autoimmune hepatitis (AIH). Immunofluorescence assay was used to observe the activated expression levels of RIP3 and its downstream signal mixed lineage protein kinase domain-like protein (MLKL) in the liver tissues of patients with AIH and hepatic cyst. Concanavalin A (ConA) was injected into the tail vein to induce acute immune-mediated hepatitis in mice. Intervention was performed by intraperitoneal injection of RIP3 inhibitor GSK872 or solvent carrier. Peripheral blood and liver tissues were collected. Serum transaminases level, qPCR and flow cytometry were analyzed. The intergroup comparison was performed with an independent sample -test. The expression level of p-RIP3 (the activated forms of RIP3) and phosphorylated p-MLKL (MLKL after phosphorylation) downstream signal were significantly higher in the liver tissue of AIH patients than those of controls. Compared with the control group, the expression levels of RIP3 and MLKL mRNA were significantly increased in the liver tissue of AIH patients (relative expression levels 3.28±0.29 . 0.98±0.09, 4.55±0.51 . 1.06±0.11), and the differences were statistically significant (=6.71 and 6.77, respectively, and <0.01). The expression levels of RIP3 and MLKL mRNA were significantly higher in the mice liver tissue of ConA-induced immune hepatitis than those in the control group (relative expression levels 2.35±0.09 . 0.89±0.11,2.77±0.22 . 0.73±0.16,=10.4,6.33, <0.01). RIP3 inhibitor GSK872 had significantly attenuated ConA-induced immune liver injury and inhibited the expression of tumor necrosis factor-α, interleukin-6, interleukin-1β and NLRP3 in liver. Compared with the control group, the proportions of CD45F4/80 macrophages, CD4 IL-17 Th17 cells, CD4 CD25 regulatory T (Treg) cells and CD11b Gr-1 myeloid derived suppressor cells (MDSCs) were significantly increased in the liver of ConA + Vehicle group. Compared with ConA + Vehicle group, the proportion of CD45F4/80 macrophages and CD4 IL-17 Th17 cells were significantly decreased, while the proportion of CD4 CD25Treg cells and CD11b Gr-1 MDSCs with immunomodulatory functions were significantly increased in mice liver of ConA+GSK872 group. AIH patients and ConA-induced immune hepatitis mice have activated RIP3 signal in liver tissues. Inhibition of RIP3 reduces the expression and proportion of proinflammatory factors and cells, and promotes the accumulation of CD4 CD25 Treg cells and CD11b Gr-1 MDSCs with immunomodulatory functions in the liver of mice with immune hepatitis, thereby alleviating liver inflammation and injury. Therefore, the inhibition of RIP3 is expected to be a new approach for the treatment of AIH.
评估受体相互作用蛋白3(RIP3)作为自身免疫性肝炎(AIH)治疗靶点的潜力。采用免疫荧光法观察AIH患者和肝囊肿患者肝组织中RIP3及其下游信号混合谱系蛋白激酶结构域样蛋白(MLKL)的活化表达水平。将刀豆蛋白A(ConA)注入小鼠尾静脉以诱导急性免疫介导性肝炎。通过腹腔注射RIP3抑制剂GSK872或溶剂载体进行干预。收集外周血和肝组织。分析血清转氨酶水平、qPCR和流式细胞术。采用独立样本t检验进行组间比较。AIH患者肝组织中p-RIP3(RIP3的活化形式)和磷酸化p-MLKL(磷酸化后的MLKL)下游信号的表达水平显著高于对照组。与对照组相比,AIH患者肝组织中RIP3和MLKL mRNA的表达水平显著升高(相对表达水平分别为3.28±0.29、0.98±0.09、4.55±0.51、1.06±0.11),差异具有统计学意义(分别为6.71和6.77,P<0.01)。ConA诱导的免疫性肝炎小鼠肝组织中RIP3和MLKL mRNA的表达水平显著高于对照组(相对表达水平分别为2.35±0.09、0.89±0.11、2.77±0.22、0.73±0.16,t=10.4、6.33,P<0.01)。RIP3抑制剂GSK872显著减轻了ConA诱导的免疫性肝损伤,并抑制了肝组织中肿瘤坏死因子-α、白细胞介素-6、白细胞介素-1β和NLRP3的表达。与对照组相比,ConA+溶剂组小鼠肝脏中CD45F4/80巨噬细胞、CD4 IL-17 Th17细胞、CD4 CD25调节性T(Treg)细胞和CD11b Gr-1髓源性抑制细胞(MDSC)的比例显著增加。与ConA+溶剂组相比,ConA+GSK872组小鼠肝脏中CD45F4/80巨噬细胞和CD4 IL-17 Th17细胞的比例显著降低,而具有免疫调节功能的CD4 CD25 Treg细胞和CD11b Gr-1 MDSC的比例显著增加。AIH患者和ConA诱导的免疫性肝炎小鼠肝组织中RIP3信号被激活。抑制RIP3可降低免疫性肝炎小鼠肝脏中促炎因子和细胞的表达及比例,并促进具有免疫调节功能的CD4 CD25 Treg细胞和CD11b Gr-1 MDSC的积累,从而减轻肝脏炎症和损伤。因此,抑制RIP3有望成为治疗AIH的新方法。